Keymed Biosciences Inc. (HKG:2162)

Market Cap	11.12B
Revenue (ttm)	455.60M
Net Income (ttm)	-548.31M
Shares Out	275.60M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,000
Average Volume	1,993,092
Open	40.25
Previous Close	40.35
Day's Range	40.90 - 42.05
52-Week Range	27.05 - 49.60
Beta	-0.03
RSI	44.17
Earnings Date	May 27, 2025

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, focuses on in-house discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis (SAR), prurigo nodularis, and respiratory related indications. The company is also developing CM512, which is in Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and imm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,258
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2162

Financial Performance

In 2024, Keymed Biosciences's revenue was 428.12 million, an increase of 20.91% compared to the previous year's 354.10 million. Losses were -515.24 million, 43.4% more than in 2023.

Financial numbers in CNY